Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
End-Stage Liver Disease in a State Prison Population
Jacques Baillargeon
, Roger D Soloway
, David Paar
, Thomas P. Giordano
, Owen Murray
, James Grady
, Brie Williams
, John Pulvino
, Ben G. Raimer
Epidemiology
Research output
:
Contribution to journal
›
Article
›
peer-review
23
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'End-Stage Liver Disease in a State Prison Population'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
End-stage Liver Disease
100%
Prison Population
100%
State Prison
100%
Hepatitis C Virus
37%
Prison System
37%
Texas
25%
Offenders
25%
Hispanic
12%
Treatment Options
12%
Mortality Rate
12%
Epidemiology
12%
Treatment Strategy
12%
Demographic Data
12%
Prevention Strategies
12%
Prevalence Rate
12%
Liver Transplantation
12%
Staggering
12%
Hepatitis C Treatment
12%
Care Program
12%
Clinical Characteristics
12%
Age 50
12%
Immunosuppressive Therapy
12%
Disease-specific Mortality
12%
Disease Prevalence
12%
Organ Transplantation
12%
Liver-related Mortality
12%
Large State
12%
Correctional Health Care
12%
Health Budget
12%
HIV-hepatitis C Virus Coinfection
12%
Prevalence Characteristics
12%
Medical Data
12%
Transplantation Therapy
12%
Correctional Population
12%
Medicine and Dentistry
End Stage Liver Disease
100%
Hepatitis C Virus
62%
Human Immunodeficiency Virus
37%
Mortality Rate
12%
Cohort Effect
12%
Prevalence
12%
Health Care Cost
12%
Immunosuppressive Treatment
12%
Mixed Infection
12%
Liver Transplantation
12%
Organ Transplantation
12%
Disease Prevalence
12%
Treatment Option
12%
Nursing and Health Professions
End Stage Liver Disease
100%
Hepatitis C
62%
Human Immunodeficiency Virus
37%
Prevalence
25%
Mortality Rate
12%
Health Program
12%
Liver Transplantation
12%
Immunosuppressive Treatment
12%
Mixed Infection
12%
Organ Transplantation
12%
Pharmacology, Toxicology and Pharmaceutical Science
End Stage Liver Disease
100%
Hepatitis C Virus
62%
HIV
37%
Prevalence
25%
Mortality Rate
12%
Immunosuppressive Agent
12%
Mixed Infection
12%